The news just keeps on coming on Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) immunology blockbuster Dupixent (dupilumab).
Recent updates have included its approval by the European Commission for children aged six to 11 years with severe asthma with type 2 inflammation and the US Food and Drug Administration (FDA) accepting a Priority Review of the supplemental Biologics License Application (sBLA) in patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus.
"The launch of high-price Dupixent for adolescents and adults is expected to increase sales in this space significantly"Data and analytics company GlobalData has predicted that Dupixent will likely see a label expansion to young EoE patients soon after approval in adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze